Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179249 | 0.92 | S1PR1 (0.34) | S1PR1S1PR3NPC1ALDH1A1RAB9A | |
| SCHEMBL1178757 | 0.91 | NPC1 (0.33) | S1PR1S1PR3NPC1ALDH1A1RAB9A | |
| SCHEMBL1178943 | 0.85 | S1PR1 (0.35) | S1PR1S1PR3NPC1ALDH1A1RAB9A | |
| SCHEMBL1179884 | 0.83 | NPC1 (0.35) | S1PR1S1PR3NPC1ALDH1A1RAB9A | |
| SCHEMBL1178671 | 0.81 | GRM5 (0.35) | S1PR1NPC1ALDH1A1RAB9A | |
| SCHEMBL1180025 | 0.79 | GRM5 (0.32) | NPC1RAB9A | |
| SCHEMBL1424804 | 0.77 | S1PR1 (0.50) | S1PR1S1PR3NPC1ALDH1A1RAB9A | |
| SCHEMBL1424912 | 0.76 | S1PR1 (0.51) | S1PR1S1PR3NPC1ALDH1A1RAB9A | |
| SCHEMBL1424727 | 0.76 | S1PR1 (0.49) | S1PR1S1PR3NPC1ALDH1A1RAB9A | |
| SCHEMBL1425070 | 0.76 | S1PR1 (0.49) | S1PR1S1PR3NPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | claimed |
| EP-2262800-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-22 | — | — | EP | claimed |
| WO-2009109907-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | claimed |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| EP-2262800-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009109907-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | TYMP, DPYD, ENTPD5 | S1PR1 766/4885S1PR3 709/4885NPC1 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.